Ceritinib, with an overall response rate of 56% and median PFS of 7 months, is effective in ALK-positive metastatic NSCLC patients who progress during or are intolerant to crizotinib treatment [5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.